Wyeth Ghostwriting Scandal: Fraudulent Pharma Research Ethics
This paper examines the ethical violations committed by Wyeth Pharmaceuticals in its use of ghostwritten, fabricated research to promote Prempro, a menopausal hormone therapy. Drawing on Fugh-Berman's (2010) analysis of publication planning in the pharmaceutical industry, the paper outlines how falsified research placed in peer-reviewed medical journals misled physicians, contributed to breast cancer diagnoses among thousands of patients, and undermined public trust in medicine and regulatory institutions. The paper further analyzes the consequences for Wyeth, the victims, and society, and proposes legal and regulatory remedies — including aggressive punitive damages and stronger FDA oversight — as necessary deterrents against systemic research fraud.
- Introduction: Wyeth and the Prempro Ghostwriting Case: Wyeth's use of ghostwritten journals to promote Prempro
- Publication Planning as a Systemic Ethical Problem: Industry-wide practice of fabricating research for marketing
- Harm to Patients and Society: Thousands harmed; public trust in medicine eroded
- Consequences for Wyeth and the Victims: Financial gains, class action damages, and reputational loss
- Legal and Regulatory Remedies: Punitive damages and FDA oversight as deterrents
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its ethical analysis in a concrete, documented case — the Wyeth/Prempro class action — giving abstract claims about research fraud a tangible, consequential context.
- It systematically traces harm outward from the individual victims to the company, then to society at large, demonstrating a multi-stakeholder view of ethical responsibility.
- The proposed remedies are logically connected to the diagnosis: because misconduct is financially motivated, the paper argues that increasing economic costs (punitive damages, FDA penalties) is the most effective corrective.
Key academic technique demonstrated
The paper uses a real-world legal case to anchor a broader ethical argument — a technique known as case-based reasoning. Rather than treating ethics abstractly, it uses the Wyeth litigation as evidence of systemic failure, then scales the analysis from individual harm to institutional trust. Citing a peer-reviewed source (Fugh-Berman, 2010) to define publication planning gives the argument scholarly grounding.
Structure breakdown
The paper opens by identifying the specific ethical violation and its mechanism (ghostwritten journals). It then contextualizes the case within the broader industry practice of publication planning. Next, it catalogs consequences at three levels — patients, the company, and society — before closing with two policy-level solutions (legal and regulatory). This funnel-to-solution structure is typical of applied ethics writing at the undergraduate level.
Introduction: Wyeth and the Prempro Ghostwriting Case
The unethical research behavior examined here was conducted by Wyeth, and is symptomatic of systemic problems within the pharmaceutical industry. The case involves class action litigation against Wyeth and centers on the ethical issue of fraudulent research. The allegation is that Wyeth fabricated research by using vendors to produce ghostwritten manuscripts and place them into medical journals. The research was therefore entirely fraudulent, yet was passed off in peer-reviewed journals as legitimate science. The objective of placing this research in journals was to legitimize a new drug Wyeth was about to launch: Prempro, a menopausal hormone therapy.
Publication Planning as a Systemic Ethical Problem
The larger issue is publication planning, described by Fugh-Berman (2010) as "the process by which pharmaceutical, biotech and medical device companies produce and release articles in medical journals and posters at meetings to establish key marketing messages." These companies use academics to produce the articles, and for both parties the practice represents a significant breach of ethics.
The ghostwriters have a duty of care as academics to produce only research that meets genuine scholarly rigor; instead, they falsify results to match predetermined marketing messages. For the companies, there is an equivalent duty of care — to their customers and to the FDA — to sell only products that offer a tangible benefit, one the FDA determines outweighs the risks of using the drug. Both obligations are violated when publication planning drives research outcomes rather than evidence.
Works Cited
Fugh-Berman, A. (2010). The haunting of medical journals: How ghostwriting sold "HRT." PLOS Medicine, 7(9). Retrieved October 31, 2012, from http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000335
Already a member? Log in
Unlock the rest of this paper
135,000+ research papers · AI writing tools · Plagiarism & AI detection
7-Day Pass
Does not renew
Get 7-Day PassMonthly
Renews at $12.99/month until canceled
Start MonthlyAnnual
Renews at $99/year until canceled
Start Annual- Unlimited AI writing tools
- Plagiarism and AI text detection tool
Plan details
Unlimited AI writing tools are for individual, non-automated use and are subject to our Terms of Service and abuse-prevention measures.
TextChecker scans: 3 during the 7-Day Pass, or 5 per month with Monthly and Annual.
Prices exclude applicable tax.
Always verify citation format against your institution’s current style guide requirements.